228 related articles for article (PubMed ID: 19854252)
1. Novel pMDI formulations for pulmonary delivery of proteins.
Li HY; Seville PC
Int J Pharm; 2010 Jan; 385(1-2):73-8. PubMed ID: 19854252
[TBL] [Abstract][Full Text] [Related]
2. The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery.
Li HY; Song X; Seville PC
Eur J Pharm Sci; 2010 Apr; 40(1):56-61. PubMed ID: 20188824
[TBL] [Abstract][Full Text] [Related]
3. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers.
Liao YH; Brown MB; Jones SA; Nazir T; Martin GP
Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753
[TBL] [Abstract][Full Text] [Related]
4. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.
Tarara TE; Hartman MS; Gill H; Kennedy AA; Weers JG
Pharm Res; 2004 Sep; 21(9):1607-14. PubMed ID: 15497686
[TBL] [Abstract][Full Text] [Related]
5. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers.
Nyambura BK; Kellaway IW; Taylor KM
Int J Pharm; 2009 Jun; 375(1-2):114-22. PubMed ID: 19481697
[TBL] [Abstract][Full Text] [Related]
6. A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers.
D'Sa D; Chan HK
Curr Pharm Des; 2015; 21(27):3955-65. PubMed ID: 26290200
[TBL] [Abstract][Full Text] [Related]
7. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
Hoe S; Young PM; Rogueda P; Traini D
AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
[TBL] [Abstract][Full Text] [Related]
8. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
Wu L; Al-Haydari M; da Rocha SR
Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
[TBL] [Abstract][Full Text] [Related]
9. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
10. Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient.
Lewis DA; Young PM; Buttini F; Church T; Colombo P; Forbes B; Haghi M; Johnson R; O'Shea H; Salama R; Traini D
Eur J Pharm Biopharm; 2014 Jan; 86(1):31-7. PubMed ID: 23523547
[TBL] [Abstract][Full Text] [Related]
11. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology.
Kleinstreuer C; Shi H; Zhang Z
J Aerosol Med; 2007; 20(3):294-309. PubMed ID: 17894536
[TBL] [Abstract][Full Text] [Related]
12. Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers.
Doub WH; Shah V; Limb S; Guo C; Liu X; Ngo D
J Pharm Sci; 2014 Nov; 103(11):3648-3656. PubMed ID: 25228114
[TBL] [Abstract][Full Text] [Related]
13. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
[TBL] [Abstract][Full Text] [Related]
14. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.
Sheth P; Stein SW; Myrdal PB
Int J Pharm; 2013 Oct; 455(1-2):57-65. PubMed ID: 23911912
[TBL] [Abstract][Full Text] [Related]
15. Multimodal particle size distributions emitted from HFA-134a solution pressurized metered-dose inhalers.
Smyth HD; Hickey AJ
AAPS PharmSciTech; 2003; 4(3):E38. PubMed ID: 14621970
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of metered dose inhaler spray velocities using phase Doppler anemometry (PDA).
Liu X; Doub WH; Guo C
Int J Pharm; 2012 Feb; 423(2):235-9. PubMed ID: 22183132
[TBL] [Abstract][Full Text] [Related]
17. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
18. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
19. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics.
Selvam P; Bharatwaj B; Porcar L; da Rocha SR
Int J Pharm; 2012 Jan; 422(1-2):428-35. PubMed ID: 22044539
[TBL] [Abstract][Full Text] [Related]
20. Plume temperature emitted from metered dose inhalers.
Brambilla G; Church T; Lewis D; Meakin B
Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
